Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Cirrhosis

Free Subscription Articles published in Clin Res Hepatol Gastroenterol Retrieve available abstracts of 102 articles: HTML format

Single Articles

August 2026
1. SURESH KB, Bhatia R, Sajawal M, Sabet O, et al
   Gene-environment interaction between heavy alcohol use and PNPLA3 rs738409 in incident cirrhosis: Evidence from a diverse U.S. cohort.
   Clin Res Hepatol Gastroenterol. 2026;50:102909.
   PubMed     Abstract available
   
   
   
2. ABDELHALIM M, Dar SF, Genidy AM, Sehsah TM, et al
   Endoscopic Sleeve Gastroplasty for Super Morbid Obesity in Compensated Liver Cirrhosis: Expanding Minimally Invasive Options for High?Risk Patients.
   Clin Res Hepatol Gastroenterol. 2026 Aug 18:102908.
   PubMed    
   
   
   
3. YAGNIK N
   Interpreting the Global Burden of Multidrug Resistance in Hospitalized Patients with Cirrhosis.
   Clin Res Hepatol Gastroenterol. 2026 Aug 13:102905.
   PubMed    
   
   
   
4. JIANG T, Cui XP, Yin YS, Xu DQ, et al
   Management of Portal Vein Thrombosis in Cirrhosis: Risks, Treatments, and Outcomes of a Retrospective Multicenter Study With Over 10 Years of Follow-Up.
   Clin Res Hepatol Gastroenterol. 2026 Aug 13:102902.
   PubMed     Abstract available
   
   
   
5. KALAL CR, Gupta P
   Reticulocalbin 3 in cirrhosis: liver biomarker or marker of systemic decompensation?
   Clin Res Hepatol Gastroenterol. 2026 Aug 10:102903.
   PubMed    
   
   
   
6. CHEN Y, Su Y, Li Y
   Comment on "Predictors of in-hospital mortality among patients with cirrhosis and renal replacement therapy in the ICU: a retrospective cohort study".
   Clin Res Hepatol Gastroenterol. 2026;50:102900.
   PubMed    
   
   
   
7. KAGZI Y, Asif A, Wang Y, Fischer J, et al
   Evaluating performance of non-invasive tests for fibrosis detection in MASLD with Type 2 Diabetes Mellitus: Insights from VCTE-Based assessment.
   Clin Res Hepatol Gastroenterol. 2026;50:102879.
   PubMed     Abstract available
   
   
   
8. MA X, Huang C, Shi H, Wang Q, et al
   Clinical features of anti-gp210-positive, AMA-negative patients with abnormal liver function.
   Clin Res Hepatol Gastroenterol. 2026;50:102846.
   PubMed     Abstract available
   
   
   July 2026
9. HSAIRI M, Feki M, Guirat M, Loukil M, et al
   Rapidly progressive cirrhosis and portal hypertension in a Tunisian child with PFIC5 due to a novel homozygous NR1H4 frameshift mutation.
   Clin Res Hepatol Gastroenterol. 2026 Jul 28:102896.
   PubMed    
   
   
   
10. ELSABAAWY M, Ragab M, Al-Khalifa M, Gamil K, et al
    Sarcopenia in Decompensated Cirrhosis: A Comparative Analysis of Bioelectrical Impedance-Based Measures.
    Clin Res Hepatol Gastroenterol. 2026 Jul 28:102893.
    PubMed     Abstract available
    
    
    
11. BADWEI N, El-Folly RF, Abdu Hemdan HA, Mohamed Wassif GO, et al
    Delayed Mortality After Successful Hemostasis in Cirrhotic Upper Gastrointestinal Bleeding: A Prospective Observational Study.
    Clin Res Hepatol Gastroenterol. 2026 Jul 14:102886.
    PubMed    
    
    
    
12. CHEN Z, Zhu W, Liu G, Yu B, et al
    Integrative Analysis of Genetic and Cellular Interactions Connecting Inflammatory Bowel Disease and Primary Biliary Cholangitis.
    Clin Res Hepatol Gastroenterol. 2026 Jul 14:102885.
    PubMed     Abstract available
    
    
    June 2026
13. SUFFERT LC, Pergher EAB, de Abreu HS, Abreu ES, et al
    Burden and Distribution of Multidrug-Resistant Bacteria Among Hospitalized Patients with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2026 Jun 30:102877.
    PubMed     Abstract available
    
    
    
14. FISCHER SE, van Ruijven B, Kerbert AJC, Fiocco M, et al
    Dipstick urinary chloride as a surrogate marker of urinary sodium in cirrhosis: a prospective multicenter pilot study.
    Clin Res Hepatol Gastroenterol. 2026 Jun 16:102871.
    PubMed     Abstract available
    
    
    May 2026
15. BADWEI N, El-Folly RF, Hemdan HAA, Wassif GOM, et al
    Early infection is associated with a distinct high-risk inflammatory-circulatory profile in cirrhotic patients presenting with acute upper gastrointestinal bleeding.
    Clin Res Hepatol Gastroenterol. 2026 May 11:102843.
    PubMed    
    
    
    
16. PENG L, Dai Y
    Prevalence of anti-mitochondrial antibodies and clinical features in autoimmune hepatitis (AIH) patients.
    Clin Res Hepatol Gastroenterol. 2026;50:102810.
    PubMed     Abstract available
    
    
    April 2026
17. HOEMANN BL, Kollef MH, Vijayan A, Michelson AP, et al
    Predictors of in-hospital mortality among patients with cirrhosis and renal replacement therapy in the ICU: a retrospective cohort study.
    Clin Res Hepatol Gastroenterol. 2026 Apr 1:102821.
    PubMed     Abstract available
    
    
    
18. ESPEROUZ F, Villani R, Ciavarella D, Serviddio G, et al
    How do oral pathogenic bacteria potentially contribute to inflammatory processes in autoimmune liver disease? Results from a systematic review.
    Clin Res Hepatol Gastroenterol. 2026;50:102797.
    PubMed     Abstract available
    
    
    March 2026
19. MOKKAPATI A, Thakkar R, Rani A, Puri D, et al
    Comment on "Sequential Anticoagulation with LMWH and DOACs in Cirrhotic Portal Vein Thrombosis".
    Clin Res Hepatol Gastroenterol. 2026 Mar 10:102806.
    PubMed     Abstract available
    
    
    
20. CHODNICKA P, Jurkiewicz E, Janowski K, Janowska M, et al
    Sensitivity and specificity of magnetic resonance elastography in liver diseases in the pediatric age group.
    Clin Res Hepatol Gastroenterol. 2026;50:102768.
    PubMed     Abstract available
    
    
    February 2026
21. ONAY M, Heilani M, Gulia C, Matthias C, et al
    Sequential Anticoagulation with LMWH and DOACs in Cirrhotic Portal Vein Thrombosis.
    Clin Res Hepatol Gastroenterol. 2026 Feb 23:102792.
    PubMed     Abstract available
    
    
    
22. BEYENE E, Chirumamilla L, Bisrat M, Bowen A, et al
    Liver gains beyond glycemic control: GLP-1 vs. SGLT2 in metabolic dysfunction-associated steatohepatitis (MASH): A real-world data analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102760.
    PubMed     Abstract available
    
    
    
23. DING C, Xing Y, Liang S, Wang C, et al
    Rifaximin for Primary prophylaxis of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A cohort analysis.
    Clin Res Hepatol Gastroenterol. 2026;50:102751.
    PubMed     Abstract available
    
    
    January 2026
24. DONGIER A, Louis E, Loly JP, Dandoy P, et al
    QuantiFERON-Monitor as Prognostic Marker of Mortality in Patients with Decompensated Cirrhosis: a Prospective Cohort Study.
    Clin Res Hepatol Gastroenterol. 2026 Jan 26:102776.
    PubMed     Abstract available
    
    
    December 2025
25. TIROTTA D, Lena C, Torre M, Muratori P, et al
    Hematologic Focal Hepatic Lesions in the Absence of Liver Cirrhosis: Consider Lymphoma and Myeloma.
    Clin Res Hepatol Gastroenterol. 2025 Dec 16:102749.
    PubMed     Abstract available
    
    
    
26. LEPOUR M, Delorme A, Goffaux A, Trefois P, et al
    Low muscle density and Five Times Sit-to-Stand Test predict poor outcome in liver transplant candidates.
    Clin Res Hepatol Gastroenterol. 2025 Dec 10:102743.
    PubMed     Abstract available
    
    
    
27. MARTINEZ-SANCHEZ FD, Agurre-Villarreal D, Argaiz ER, Rosales-Renteria LA, et al
    Physiology-Guided Albumin Therapy in Decompensated Cirrhosis: The Expanding Role of Point-of-Care Ultrasound.
    Clin Res Hepatol Gastroenterol. 2025 Dec 9:102744.
    PubMed     Abstract available
    
    
    October 2025
28. MARYAM A, Naghshzan A, Mahmood H, Mohsen D, et al
    Cirrhotic Cardiomyopathy in Children: A Comprehensive Assessment Using ECG, Echocardiography, and NT-Pro-BNP.
    Clin Res Hepatol Gastroenterol. 2025 Oct 28:102721.
    PubMed     Abstract available
    
    
    September 2025
29. HAIDER S
    Proton Pump Inhibitors Versus H2-Receptor Antagonists in Cirrhotic Patients: A Clinical Case and Literature Perspective.
    Clin Res Hepatol Gastroenterol. 2025 Sep 2:102681.
    PubMed    
    
    
    
30. HEXNER-ERLICHMAN Z, Assy N, Habashi N, Yousif A, et al
    Multiorgan fibrosis in Gaucher disease type I: an unmet goal of enzyme replacement therapy.
    Clin Res Hepatol Gastroenterol. 2025;49:102677.
    PubMed     Abstract available
    
    
    
31. RATTANAPITOON NK, La N, Rattanapitoon SK
    Reconsidering the post-SVR landscape: Clinical implications of rising steatosis despite fibrosis regression.
    Clin Res Hepatol Gastroenterol. 2025;49:102661.
    PubMed     Abstract available
    
    
    August 2025
32. SOPHASATH M, Tremblay M, Hogue C, Brisset A, et al
    Evaluation of a nutritional education guide designed for patients living with cirrhosis: A randomized controlled mixed-methods study.
    Clin Res Hepatol Gastroenterol. 2025;49:102672.
    PubMed     Abstract available
    
    
    
33. JABER H, Chehayeb S, Nasr J, Souky NA, et al
    Proton Pump Inhibitor Use and Risk of Hepatic Encephalopathy in Cirrhotic Patients: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2025 Aug 12:102667.
    PubMed     Abstract available
    
    
    July 2025
34. BROWN C
    A call for increased advocacy and universal resources to support effective nutritional interventions in the comprehensive management of patients with cirrhosis.
    Clin Res Hepatol Gastroenterol. 2025;49:102650.
    PubMed    
    
    
    
35. SUALEHEEN A, Tan SY, Daly RM, Georgousopoulou E, et al
    Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population.
    Clin Res Hepatol Gastroenterol. 2025;49:102649.
    PubMed     Abstract available
    
    
    
36. XU L, Yin B, Chen D, Xiong X, et al
    Specific association and independent predictive value of HBV RNA in the disease progression of hepatitis B with low-level viremia.
    Clin Res Hepatol Gastroenterol. 2025;49:102648.
    PubMed     Abstract available
    
    
    
37. CARRIER P, Chalange M, Girard M, Premaud A, et al
    Liver fibrosis evaluation in patients with psychiatric diseases.
    Clin Res Hepatol Gastroenterol. 2025;49:102636.
    PubMed     Abstract available
    
    
    
38. XU X, Zhao H, Zhang J, Yan H, et al
    Interleukin-22 ameliorates alcohol-associated liver fibrosis via Nrf2-ARE signaling: mechanistic insights and clinical correlations.
    Clin Res Hepatol Gastroenterol. 2025;49:102617.
    PubMed     Abstract available
    
    
    June 2025
39. SHENGIR M, Elgretli W, Cinque F, Ramanakumar AV, et al
    Metabolic Factors Drive Early Increase in Hepatic Steatosis Despite Improvement in Non-Invasive Fibrosis Markers after Hepatitis C Eradication with Direct-Acting Antivirals.
    Clin Res Hepatol Gastroenterol. 2025 Jun 16:102639.
    PubMed     Abstract available
    
    
    
40. BEN YEDDER N, Girot P, Koudougou C, Schnee M, et al
    Lack of prior screening for advanced liver fibrosis in patients with newly diagnosed hepatocellular carcinoma: Results from a prospective multicentre study.
    Clin Res Hepatol Gastroenterol. 2025;49:102607.
    PubMed     Abstract available
    
    
    
41. GOYAL RM, Bansal B, Ayyad M, Singh A, et al
    Clinical outcomes in patients with autoimmune hepatitis and primary biliary cholangitis overlap syndrome in the United States.
    Clin Res Hepatol Gastroenterol. 2025;49:102598.
    PubMed     Abstract available
    
    
    May 2025
42. KARIYAMA K, Toyoda H, Kumada T, Yasuda S, et al
    Utility of the Fibrosis-3 Index for Predicting Liver Fibrosis 5 Years After Achieving Sustained Virological Response in Patients with Chronic Hepatitis C.
    Clin Res Hepatol Gastroenterol. 2025 May 27:102625.
    PubMed     Abstract available
    
    
    
43. LEE CH, Kang MG, Oh S, Gwak IS, et al
    Hepatocellular carcinoma risk in ICD-coded non-cirrhotic nonalcoholic fatty liver disease refined by fatty liver index: A nationwide South Korean cohort study.
    Clin Res Hepatol Gastroenterol. 2025;49:102612.
    PubMed     Abstract available
    
    
    
44. VILLAVICENCIO EA, Serdjebi C, Maldonado A, Ochoa Mora E, et al
    Use of Hepatoscope 2DTE for non-invasive assessment of liver stiffness among Mexican immigrant adults in a community-based setting.
    Clin Res Hepatol Gastroenterol. 2025;49:102581.
    PubMed     Abstract available
    
    
    April 2025
45. TATOUR M, Baker FA, Saadi T, Yahia A, et al
    Advancements in autoimmune hepatitis epidemiology, treatment and complication - a 15-year retrospective study.
    Clin Res Hepatol Gastroenterol. 2025;49:102570.
    PubMed     Abstract available
    
    
    
46. LANTHIER N, Spahr L
    Macrophage therapy and liver regeneration: Results and perspectives.
    Clin Res Hepatol Gastroenterol. 2025;49:102569.
    PubMed     Abstract available
    
    
    March 2025
47. HE Y, Ye M, Xia Y, Zhong Z, et al
    The role of cytokines as predictors for NAFLD-related diseases: A bidirectional Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2025;49:102545.
    PubMed     Abstract available
    
    
    
48. ABDEL MONEM MS, Adel A, Abbassi MM, Abdelaziz DH, et al
    Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial.
    Clin Res Hepatol Gastroenterol. 2025;49:102543.
    PubMed     Abstract available
    
    
    February 2025
49. LIU Z, Yang X, Jiang H, Xie R, et al
    Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis.
    Clin Res Hepatol Gastroenterol. 2025 Feb 19:102553.
    PubMed     Abstract available
    
    
    January 2025
50. SASAKI M, Sato Y, Nakanuma Y
    A heterogeneous subtype of biliary epithelial senescence may be involved in the pathogenesis of primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2025;49:102512.
    PubMed     Abstract available
    
    
    November 2024
51. WANG Z, Wang Z, Li F, Cai J, et al
    Construction and Validation of a Machine Learning-Based Prediction Model for Short-Term Mortality in Critically Ill Patients with Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 30:102507.
    PubMed     Abstract available
    
    
    
52. JIANG J, Bouquet E, Kweon Y, Elsaid MI, et al
    Neighborhood Opportunity is Associated with Completion of Hepatocellular Carcinoma Surveillance Prior to the Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Nov 1:102485.
    PubMed     Abstract available
    
    
    
53. LEE YP, Chiu CC, Chang YC, Chen YH, et al
    Co-exposure to different bacterial species' lipopolysaccharides with the NASH diet exacerbates NASH and liver fibrosis progression in mice.
    Clin Res Hepatol Gastroenterol. 2024;48:102470.
    PubMed     Abstract available
    
    
    October 2024
54. ZHONG H, Lu S, Xu M, Liu N, et al
    Predictive value of hepatic venous pressure gradient in cirrhotic portal vein thrombosis development.
    Clin Res Hepatol Gastroenterol. 2024 Oct 29:102484.
    PubMed     Abstract available
    
    
    
55. DING J, He X, Lin W, Xia S, et al
    Exploring the relationship between vitamin D and hepatic carcinoma in individuals diagnosed with hepatitis B virus infection.
    Clin Res Hepatol Gastroenterol. 2024;48:102457.
    PubMed     Abstract available
    
    
    
56. CANCADO GGL, Fucuta PDS, Gomes NMF, Couto CA, et al
    Alkaline phosphatase and liver fibrosis at diagnosis are associated with deep response to ursodeoxycholic acid in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102453.
    PubMed     Abstract available
    
    
    
57. WANG M, Liu X, Qiao C, Chen R, et al
    Association of congenital hepatic fibrosis and Caroli's syndrome: Two illustrative cases.
    Clin Res Hepatol Gastroenterol. 2024;48:102443.
    PubMed    
    
    
    
58. KHONDE P, Choudhury S, Spies NC, Naz N, et al
    Worse fibro-inflammatory activity on diagnostic liver biopsy adversely impacts biochemical remission in autoimmune hepatitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102442.
    PubMed     Abstract available
    
    
    September 2024
59. HAO NB, Zhou Y, Zhang D, Li YN, et al
    Effect of sarcopenia on liver cirrhosis with complicating oesophageal and gastric varices after endoscopic therapy.
    Clin Res Hepatol Gastroenterol. 2024 Sep 10:102459.
    PubMed     Abstract available
    
    
    
60. KURNIAWAN J, Siahaan BS
    Performance of Spleen Stiffness Measurement by 100-Hz Vibration-Controlled Transient Elastography, Liver Stiffness, APRI Score and their Combination for Predicting Oesophageal Varices in Liver Cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Sep 1:102456.
    PubMed     Abstract available
    
    
    August 2024
61. GANTZEL RH, Deleuran T, Vilstrup H, Watson H, et al
    The CIRrhotic Ascites Severity (CIRAS) model predicts hepatic hydrothorax at all stages of ascites.
    Clin Res Hepatol Gastroenterol. 2024;48:102452.
    PubMed     Abstract available
    
    
    
62. EZHILARASAN D, Najimi M
    Quiescent hepatic stellate cell activation in liver fibrosis: Have we found the right trigger yet?
    Clin Res Hepatol Gastroenterol. 2024;48:102420.
    PubMed    
    
    
    
63. HU T, Tang W, Hong W, Huang Q, et al
    Spermine oxidase regulates liver inflammation and fibrosis through beta-catenin pathway.
    Clin Res Hepatol Gastroenterol. 2024;48:102421.
    PubMed     Abstract available
    
    
    
64. LIN YL, Yao T, Wang YW, Yu JS, et al
    Association between primary biliary cholangitis with diabetes and cardiovascular diseases: A bidirectional multivariable Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102419.
    PubMed     Abstract available
    
    
    
65. LI R, Lee S, Rienas W, Sarin S, et al
    Higher risk of in-hospital mortality and hepatic encephalopathy during weekend admission in Transjugular Intrahepatic Portosystemic Shunt procedure.
    Clin Res Hepatol Gastroenterol. 2024;48:102396.
    PubMed     Abstract available
    
    
    
66. JIANG R, Hua Y, Hu X, Hong Z, et al
    The pan immune inflammatory value in relation to non-alcoholic fatty liver disease and hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2024;48:102393.
    PubMed     Abstract available
    
    
    
67. HU J, Mi Y, Wang L, Jiang F, et al
    Exploring the role of mitochondrial proteins SIRT5 and MRPL33 through Mendelian randomization in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102394.
    PubMed     Abstract available
    
    
    
68. RASHU EB, Werge MP, Hetland LE, Thing M, et al
    Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
    Clin Res Hepatol Gastroenterol. 2024;48:102389.
    PubMed     Abstract available
    
    
    
69. FU H, Li H, Du Y, Liu C, et al
    Factors influencing pathological changes in the liver tissue in hepatitis B virus carriers with low-level viremia.
    Clin Res Hepatol Gastroenterol. 2024;48:102351.
    PubMed     Abstract available
    
    
    July 2024
70. BALE G, Clarembeau F, Starkel P, Dahlqvist G, et al
    Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis.
    Clin Res Hepatol Gastroenterol. 2024 Jul 22:102428.
    PubMed     Abstract available
    
    
    June 2024
71. OLIVEIRA M, Gaspar R, Santos L, Macedo G, et al
    High incidence of hepatocarcinoma in patients with advanced fibrosis treated with direct-acting antiviral agents for hepatitis C: a real-world retrospective study.
    Clin Res Hepatol Gastroenterol. 2024 Jun 18:102404.
    PubMed     Abstract available
    
    
    
72. ROGALSKI J, Czarnecka-Chrebelska K, Weglewska K, Pleska K, et al
    Abnormal liver steatosis and fibrosis serum biomarker levels among psychiatric inpatients.
    Clin Res Hepatol Gastroenterol. 2024;48:102366.
    PubMed    
    
    
    
73. TANAKA A, Corpechot C
    PPAR agonists in PBC: Where do we go from here? Or how to choose between the new and the old.
    Clin Res Hepatol Gastroenterol. 2024;48:102358.
    PubMed     Abstract available
    
    
    
74. ZHOU F, Liu X, Chang C, Liu J, et al
    Separating the effects of early and later life body mass index on liver diseases: A Mendelian randomization study.
    Clin Res Hepatol Gastroenterol. 2024;48:102352.
    PubMed     Abstract available
    
    
    May 2024
75. MANSUR A, Grobman B, Lu CY
    Suicide risk is elevated among patients with chronic liver disease and cirrhosis in the United States.
    Clin Res Hepatol Gastroenterol. 2024;48:102378.
    PubMed    
    
    
    
76. CHANG G, Sun J, Li J, Li T, et al
    Effect of Probiotics on Portal Hypertension (PH) with Cirrhosis: A Systematic Review and Meta-Analysis.
    Clin Res Hepatol Gastroenterol. 2024 May 1:102361.
    PubMed     Abstract available
    
    
    
77. LI R, Sarin S
    The smoker's paradox in transjugular intrahepatic portosystemic shunt procedure: A national inpatient sample analysis from 2015 to 2020.
    Clin Res Hepatol Gastroenterol. 2024;48:102323.
    PubMed     Abstract available
    
    
    
78. LIANG Y, Li J, Zhang Z, Jiang T, et al
    Extrahepatic conditions of primary biliary cholangitis: A systematic review and meta-analysis of prevalence and risk.
    Clin Res Hepatol Gastroenterol. 2024;48:102321.
    PubMed     Abstract available
    
    
    April 2024
79. PATEL K, Twohig P, Peeraphatdit T, Stohs EJ, et al
    Outcomes and factors associated with cryptococcal disease among cirrhotics: A study of the national inpatient sample 2005 to 2014.
    Clin Res Hepatol Gastroenterol. 2024;48:102337.
    PubMed     Abstract available
    
    
    February 2024
80. HE Q, Xiong Y, Xia P, Yang X, et al
    Predicting cancer-specific mortality in T1/2 hepatocellular carcinoma after radiofrequency ablation by competing risk nomogram: A population-based analysis.
    Clin Res Hepatol Gastroenterol. 2024;48:102283.
    PubMed     Abstract available
    
    
    
81. XIE C, Liu K, Xie Y, Liu S, et al
    Metabolism-related signalling pathways involved in the pathogenesis and development of metabolic dysfunction-associated steatotic liver disease.
    Clin Res Hepatol Gastroenterol. 2024;48:102264.
    PubMed     Abstract available
    
    
    January 2024
82. KUMAR MS
    Paneth cell: The missing link between obesity, MASH and portal hypertension.
    Clin Res Hepatol Gastroenterol. 2024;48:102259.
    PubMed     Abstract available
    
    
    
83. SEXTON F, Shanahan W, Ryan JD
    Xanthoma striatum palmare: Getting a handle on hyperlipidaemia in primary biliary cholangitis.
    Clin Res Hepatol Gastroenterol. 2024;48:102255.
    PubMed    
    
    
    December 2023
84. THABUT D, Roux J, Simon-Sultanik P, Tamberou C, et al
    Population characteristics, healthcare pathways and outcomes of patients with cirrhosis hospitalized with overt hepatic encephalopathy in France: a study of the French Hospital-Discharge Database.
    Clin Res Hepatol Gastroenterol. 2023 Dec 26:102274.
    PubMed     Abstract available
    
    
    
85. JANG H, Han N, Staatz CE, Kwak JH, et al
    Effect on lipid profile and clinical outcomes of obeticholic acid for the treatment of primary biliary cholangitis and metabolic dysfunction-associated steatohepatitis: A systematic review and meta-analysis.
    Clin Res Hepatol Gastroenterol. 2023;47:102227.
    PubMed     Abstract available
    
    
    
86. JIANG R, Zhou Y, Han L, Hong Z, et al
    Serum vitamin D is associated with ultrasound-defined hepatic fibrosis.
    Clin Res Hepatol Gastroenterol. 2023;47:102228.
    PubMed     Abstract available
    
    
    
87. DONATI A, Henrion J, Regnier M, Deltenre P, et al
    Abstinence is associated with better outcomes in patients with alcohol-related hepatocellular carcinoma: Results of an observational study.
    Clin Res Hepatol Gastroenterol. 2023;47:102225.
    PubMed     Abstract available
    
    
    October 2023
88. CHAIBI S, Larrey E, Couty JP, Sultanik P, et al
    Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC.
    Clin Res Hepatol Gastroenterol. 2023;47:102199.
    PubMed     Abstract available
    
    
    
89. DUMONT C, Lanthier N, Dahlqvist G
    Fibrosis and steatosis of the liver graft: Are non-invasive tests useful? A short review.
    Clin Res Hepatol Gastroenterol. 2023;47:102194.
    PubMed     Abstract available
    
    
    September 2023
90. MARTINO VD, Questiaux J, Lemagoarou T, Weil D, et al
    Granulocyte Colony Stimulating Factor in decompensated cirrhosis, acute alcoholic hepatitis, and acute-on-chronic liver failure: a comprehensive meta-analysis of randomized controlled trials.
    Clin Res Hepatol Gastroenterol. 2023 Sep 14:102207.
    PubMed     Abstract available
    
    
    
91. KOUNIS I, Sacleux SC, Ordan MA, Andre S, et al
    Efficiency and safety of total plasma exchange in critically ill cirrhotic patients with acute on chronic liver failure: A pilot study.
    Clin Res Hepatol Gastroenterol. 2023;47:102206.
    PubMed     Abstract available
    
    
    August 2023
92. LU M, Zhu M, Li H, Wang Q, et al
    Factors associated with discordance in the assessment of fibrosis stage between transient elastography and liver biopsy in NAFLD patients.
    Clin Res Hepatol Gastroenterol. 2023;47:102183.
    PubMed     Abstract available
    
    
    
93. MAMANDIPOOR B, Wernly S, Semmler G, Flamm M, et al
    Machine learning models predict liver steatosis but not liver fibrosis in a prospective cohort study.
    Clin Res Hepatol Gastroenterol. 2023;47:102181.
    PubMed     Abstract available
    
    
    
94. CALLERI A, Alessandria C
    Renal damage in Hepatorenal Syndrome: A still unsolved issue.
    Clin Res Hepatol Gastroenterol. 2023;47:102178.
    PubMed     Abstract available
    
    
    June 2023
95. WANG X, Xu GH, Yu J, Li H, et al
    When cirrhosis meets paroxysmal nocturnal hemoglobinuria: What kind of "fireworks" scenario will occur?
    Clin Res Hepatol Gastroenterol. 2023;47:102173.
    PubMed    
    
    
    May 2023
96. YAICI L, Gatouillat G, Andreoletti L, N'Guyen Y, et al
    Chronic Hepatitis Delta cirrhosis cured by adapting PEG-IFNalpha-2a + tenofovir disoproxil fumarate treatment duration until HBsAg loss.
    Clin Res Hepatol Gastroenterol. 2023 May 25:102148.
    PubMed     Abstract available
    
    
    
97. RAVAIOLI F, Berger A, Farcau O, Colecchia A, et al
    Individual and population screening of varices needing treatment by a simple, safe and accurate test.
    Clin Res Hepatol Gastroenterol. 2023;47:102123.
    PubMed     Abstract available
    
    
    
98. MALKANI KV, Jesudian AB, Luo JJ, Schonfeld EA, et al
    Noncirrhotic portal hypertension in primary biliary cholangitis with coexisting CREST syndrome.
    Clin Res Hepatol Gastroenterol. 2023;47:102114.
    PubMed     Abstract available
    
    
    
99. MEURER A, Antoni C, Ebert MP, Trimborn A, et al
    Spontaneous bacterial peritonitis caused by Listeria monocytogenes: A rare infection with very high leukocyte counts in ascitic fluid-case report and review of the literature.
    Clin Res Hepatol Gastroenterol. 2023;47:102130.
    PubMed     Abstract available
    
    
    April 2023
100. SASAKI M, Sato Y, Nakanuma Y
     An involvement of Hippo-yes-associated protein pathway in biliary epithelial senescence in primary biliary cholangitis.
     Clin Res Hepatol Gastroenterol. 2023;47:102106.
     PubMed     Abstract available
     
     
     March 2023
101. CAO L, Qu N, Wang X, Chen L, et al
     The function of long non-coding RNA in non-alcoholic fatty liver disease.
     Clin Res Hepatol Gastroenterol. 2023;47:102095.
     PubMed     Abstract available
     
     
     February 2023
102. IANNONE G, Pompili E, Renzulli M, Caraceni P, et al
     A case of peri-stomal ectopic variceal bleeding in a patient with decompensated cirrhosis treated with TIPS placement.
     Clin Res Hepatol Gastroenterol. 2023 Feb 24:102098.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum